Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Cardinal Health (CAH) and Sanofi (OtherSNYNF)
Sanofi's Promising Portfolio Drives Buy Rating Amid MS, Cancer Breakthroughs, and Vaccine Expansion
Sanofi (SNYNF) Receives a Buy From Barclays
J.P. Morgan Sticks to Its Hold Rating for Sanofi (SNYNF)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Sanofi (OtherSNYNF)
Berenberg Bank Maintains Sanofi(SNY.US) With Buy Rating, Cuts Target Price to $64
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF) and Tandem Diabetes Care (TNDM)
Berenberg Raises Price Target on Sanofi to EUR115 From EUR105, Maintains Buy Rating
Buy Rating Affirmed for Sanofi on Strong Clinical Trial Outcomes and Promising MS Drug Pipeline
TD Cowen Maintains Sanofi(SNY.US) With Hold Rating
Sanofi (SNY) Gets a Hold From TD Cowen
Berenberg Bank Sticks to Their Buy Rating for Sanofi (SNYNF)
Buy Rating Affirmed for Sanofi Amid Promising Tolebrutinib Trials and Significant Market Opportunity
Sanofi (SNYNF) Gets a Hold From Kepler Capital
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Progyny (PGNY) and Health Catalyst (HCAT)
The latest pharmaceutical industry rating by S&P reveals that Johnson & Johnson (JNJ.US) and Roche (RHHBY.US) are ranked at the top for superior financial and innovative abilities.
Sanofi's Growth Prospects Bolstered by Promising Drug Pipeline and Strategic Corporate Actions: A Buy Rating Review
Sanofi (SNYNF) Receives a Hold From J.P. Morgan
Sanofi (SNYNF) Receives a Hold From Kepler Capital
Argus Research Maintains Buy on Sanofi, Raises Price Target to $60